Docstoc

apt_pharmaceuticals_inc_product_pipeline_review_q1_2011

Document Sample
apt_pharmaceuticals_inc_product_pipeline_review_q1_2011 Powered By Docstoc
					APT Pharmaceuticals, Inc. – Product Pipeline Review
– Q1 2011




                                    Phone:    +44 20 8123 2220
                                    Fax:      +44 207 900 3970
                                    office@marketpublishers.com

                                    http://marketpublishers.com
                                                                                     Phone: +44 20 8123 2220
                                                                                     http://marketpublishers.com



APT Pharmaceuticals, Inc. – Product Pipeline Review – Q1 2011
Global Markets Direct

Date: Mar, 2011
Pages: 31
Price: US$ 500.00
ID: AFE55E623CDEN

APT Pharmaceuticals, Inc. - Product Pipeline Review - Q1 2011

Summary

Global Market Direct’s pharmaceuticals report, “APT Pharmaceuticals, Inc. - Product Pipeline Review - Q1
2011” provides data on the company’s research and development focus. The report includes information
on current developmental pipeline, complete with latest updates, and features on discontinued and dormant
projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases,
Company’s corporate website, SEC filings, investor presentations and featured press releases, both from
company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

           APT Pharmaceuticals, Inc. - Brief company overview including business description, key information
           and facts, and its locations and subsidiaries.
           Review of current pipeline of APT Pharmaceuticals, Inc. human therapeutic division.
           Overview of pipeline therapeutics across various therapy areas.
           Coverage of current pipeline molecules in various stages of drug development, including the
           combination treatment modalities, across the globe.
           Product profiles for late stage and clinical stage products of APT Pharmaceuticals, Inc. with
           complete description of the product’s developmental history, mechanism of action, therapeutic
           class, target and major milestones.
           Recent updates of the APT Pharmaceuticals, Inc.’s pipeline in the last quarter.
           Key discontinued and dormant projects.
           Latest news and deals relating to the products.

Reasons to buy

           Evaluate APT Pharmaceuticals, Inc.’s strategic position with total access to detailed information on
           its product pipeline.
           Assess the growth potential of APT Pharmaceuticals, Inc. in its therapy areas of focus.
           Identify new drug targets and therapeutic classes in the APT Pharmaceuticals, Inc.’s R&D portfolio
           and develop key strategic initiatives to reinforce pipeline in those areas.
           Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
           Exploit collaboration and partnership opportunities with APT Pharmaceuticals, Inc..
           Avoid Intellectual Property Rights related issues.
           Explore the dormant and discontinued projects of APT Pharmaceuticals, Inc. and identify potential
           opportunities in those areas.



Table of Content
Table of Contents

APT Pharmaceuticals, Inc. – Product Pipeline Review – Q1 2011                                                      2
                                                                            Phone: +44 20 8123 2220
                                                                            http://marketpublishers.com


List of Tables
List of Figures
APT Pharmaceuticals, Inc. Snapshot
APT Pharmaceuticals, Inc. Overview
Key Information
Key Facts
APT Pharmaceuticals, Inc. – Research and Development Overview
Key Therapeutic Areas
APT Pharmaceuticals, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
APT Pharmaceuticals, Inc. – Pipeline Products Glance
APT Pharmaceuticals, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
APT Pharmaceuticals, Inc. – Drug Profiles
Inhaled Anti-Inflammatory Agent
Product Description
Mechanism of Action
R&D Progress
APT Pharmaceuticals, Inc. – Pipeline Analysis
APT Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class
APT Pharmaceuticals, Inc. – Pipeline Products by Route of Administration
APT Pharmaceuticals, Inc. - Dormant Projects
APT Pharmaceuticals, Inc. – Locations And Subsidiaries
Head Office
Recent Developments
Mar 23, 2006: Aradigm And APT Pharmaceuticals Initiates Phase 2 Clinical Program Of Novel Treatment
For Asthma
Jul 21, 2005: Aradigm Corporation (ARDM) And APT Pharmaceutical LLC Announces Progression Of
AERx HCQ Program Into Phase 2 Clinical Trials
Jul 21, 2005: Aradigm Corporation (ARDM) And APT Pharmaceutical LLC Announces Progression Of
AERx HCQ Program Into Phase 2 Clinical Trials
Jul 15, 2005: FDA Requests Additional Data On PULMINIQ Inhalation Solution
Jun 07, 2005: Chiron Expects FDA Decision On New Therapy For Lung-Transplant Patients
Nov 19, 2004: APT Completes Phase I Studies With Aerosolized Hydroxychloroquine For Asthma
Oct 14, 2004: Chiron Submits New Drug Application For PULMINIQ
Sep 13, 2004: APT Starts Human Trials Of Aerosolized Hydroxychloroquine For Asthma.
Jun 17, 2003: APT Patents Targeted Delivery Of Hydroxychloroquine For Inflammatory Diseases
Financial Deals Landscape
APT Pharmaceuticals, Inc., Deals Volume Summary, 2004 to YTD 2011
APT Pharmaceuticals, Inc., Deals Summary By Region, 2004 to YTD 2011
APT Pharmaceuticals, Inc., Deals Summary, 2004 to YTD 2011
APT Pharmaceuticals, Inc. Detailed Deal Summary
Venture Financing
APT Pharmaceuticals Secures $32.3 Million In Series B Financing
APT Pharmaceuticals Secures $22 Million In Series A-2 Round Of Funding
APT Pharmaceuticals Secures $9 Million In Series A Round Of Financing
Licensing Agreements
APT Pharmaceuticals Enters Into Licensing Agreement With Novartis Pharma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
APT Pharmaceuticals, Inc. – Product Pipeline Review – Q1 2011                                             3
                                                                            Phone: +44 20 8123 2220
                                                                            http://marketpublishers.com


Contact Us
Disclaimer

LIST OF TABLES

APT Pharmaceuticals, Inc. – Pipeline by Therapy Area and Indication, 2011
APT Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2011
APT Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2011
APT Pharmaceuticals, Inc. - Pipeline By Therapeutic Class, 2011
APT Pharmaceuticals, Inc. – Pipeline By Route of Administration, 2011
APT Pharmaceuticals, Inc. - Dormant Developmental Projects, 2010
APT Pharmaceuticals, Inc., Deals Summary, 2004 to YTD 2011
APT Pharmaceuticals, Inc., Deals Summary by Region, 2004 to YTD 2011
APT Pharmaceuticals, Inc., Deals Summary, 2004 to YTD 2011

LIST OF FIGURES
APT Pharmaceuticals, Inc. – Pipeline by Therapy Area and Indication, 2011
APT Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2011
APT Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2011
APT Pharmaceuticals, Inc. – Pipeline By Therapeutic Class, 2011




APT Pharmaceuticals, Inc. – Product Pipeline Review – Q1 2011                                             4
                                                                                                                              Phone: +44 20 8123 2220
                                                                                                                              http://marketpublishers.com




                                   I would like to order:

                                   Product name:         APT Pharmaceuticals, Inc. – Product Pipeline Review – Q1 2011
                                   Product link:         http://marketpublishers.com/r/AFE55E623CDEN.html
                                   Product ID:           AFE55E623CDEN
                                   Price:                US$ 500.00 (Single User License / Electronic Delivery)

                                   If you want to order Corporate License or Hard Copy, please, contact our Customer Service: office@marketpublishers.com


                                   Payment

                                   To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click 'BUY NOW' button
                                   on product page http://marketpublishers.com/r/AFE55E623CDEN.html




                                   To pay by Wire Transfer, please, fill in your contact details in the form below:

                                   First name:
                                   Last name:
                                   E-mail:
                                   Company:
                                   Address:
                                   City:
                                   Zip/Post Code:
                                   Country:
                                   Tel:
                                   Fax:
                                   Your message:



                                                          * All fields are required



                                   Customer Signature _______________________________________

                                   Please, note that by ordering from MarketPublisher.com you are agreeing to our Terms & Conditions at
                                   http://marketpublishers.com/docs/terms_conditions.html


                                   To place an order via fax simply print this form, fill in the information below
                                   and fax the completed form to +44 20 7900 3970




Powered by TCPDF (www.tcpdf.org)

				
DOCUMENT INFO
Shared By:
Categories:
Tags:
Stats:
views:1
posted:7/30/2012
language:
pages:5